OmnEcoil Instruments

Executive Summary

OmnEcoil Instruments is a Boston-based medical device company developing a novel system that integrates MRI-based prostate cancer detection with targeted tissue sampling into a single, streamlined procedure. Traditional prostate biopsy, guided by blind ultrasound, suffers from low accuracy and high false-negative rates, leading to missed diagnoses and unnecessary repeat procedures. The OmnEcoil device aims to overcome these limitations by combining real-time MRI imaging with precision biopsy tools, potentially improving cancer detection rates, reducing patient discomfort, and lowering healthcare costs. Founded in 2015, the company is privately held and has not disclosed funding or valuation details. While still in the development stage, the technology addresses a clear unmet need in urology, with a large addressable market given the high incidence of prostate cancer worldwide. If successful, OmnEcoil could become a standard-of-care tool for prostate cancer diagnosis, offering a more accurate and efficient alternative to current practices. The company's progress will depend on clinical validation, regulatory approvals, and securing commercial partnerships.

Upcoming Catalysts (preview)

• Q3 2026Initiation of pivotal clinical trial70% success
• TBDFDA 510(k) submission50% success
• Q3 2026Strategic partnership with major urology clinic40% success